Skip to main content

Advertisement

SpringerLink
Log in

Targeted therapy

PROTACs reach clinical development in inflammatory skin disease

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

A phase 1 trial of an IRAK4-targeted protein degrader in patients with chronic inflammatory skin diseases hits an important milestone for the safe application of this drug class beyond oncology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Targeted degradation of IRAK4 is pharmacologically different from IRAK4 kinase inhibition.

References

  1. Burslem, G. M. & Crews, C. M. Cell 181, 102–114 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Chirnomas, D., Hornberger, K. R. & Crews, C. M. Nat. Rev. Clin. Oncol. 20, 265–278 (2023).

    Article  CAS  PubMed  Google Scholar 

  3. Ackerman, L. Nat. Med. https://doi.org/10.1038/s41591-023-02635-7 (2023).

  4. McElroy, W. T. Expert Opin. Ther. Pat. 29, 243–259 (2019).

    Article  CAS  PubMed  Google Scholar 

  5. Danto, S. I. et al. Arthritis Res. Ther. 21, 269 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Matyskiela, M. E. et al. Nat. Chem. Biol. 14, 981–987 (2018).

    Article  CAS  PubMed  Google Scholar 

  7. Donovan, K. A. et al. Elife 7, e38430 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ghobrial, I. M. & Rajkumar, S. V. J. Support. Oncol. 1, 194–205 (2003).

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Volak, L. P. et al. Drug Metab. Dispos. 51, 792–803 (2023).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemistry and Biochemistry, University of California, San Diego, CA, USA

    Fleur M. Ferguson

  2. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA, USA

    Fleur M. Ferguson

Authors
  1. Fleur M. Ferguson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fleur M. Ferguson.

Ethics declarations

Competing interests

F.M.F. is a scientific co-founder and equity holder in Proximity Therapeutics, was recently a scientific advisory board (SAB) member for Triana Biomedicines, and is or recently was a consultant or received speaking honoraria from Eli Lilly and Co., RA Capital, Tocris BioTechne, Johnson & Johnson Innovative Medicine and Plexium Inc. The Ferguson lab receives or has received research funding from Ono Pharmaceutical Co. Ltd and Merck & Co.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ferguson, F.M. PROTACs reach clinical development in inflammatory skin disease. Nat Med 29, 3006–3007 (2023). https://doi.org/10.1038/s41591-023-02622-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02622-y

  • Springer Nature America, Inc.

Search

Navigation